JSPR
Jasper Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 3
consensus rating "Strong Buy"
Net Income Plunges
Bearish Abandoned Baby
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About JSPR
Jasper Therapeutics, Inc.
A biotech company focused on developing multiple new therapies for the field of stem and cellular medicine
Biological Technology
08/13/2019
01/10/2020
NASDAQ Stock Exchange
64
12-31
Common stock
2200 Bridge Pkwy Suite #102, Redwood City, CA 94065
--
Jasper Therapeutics, Inc., was incorporated in Delaware on August 13, 2019. The company is a clinical-stage biotechnology company focused on treatments for hypertrophy and hematopoietic stem cells. The company focuses on the development and commercialization of safer and more effective therapeutic drugs for the treatment of diseases such as chronic spontaneous urticaria, low to moderate risk myelodysplastic syndrome, as well as novel conditioning regimens for stem cell transplantation and in vitro gene therapy, a technology for genetically manipulating cells in vitro before transplantation.
Company Financials
EPS
JSPR has released its 2025 Q1 earnings. EPS was reported at -1.41, versus the expected -1.48, beating expectations. The chart below visualizes how JSPR has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
